Physician profile
Nina C Ramirez
NPI 1548258510
$833,355.34
in general payments reported to CMS, 2019-2025
18 companies · $192K in 2025
The $192K reported for 2025 was more than what 99% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $34K · 2021: $103K · 2022: $111K · 2023: $101K · 2024: $150K · 2025: $192K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $327K · Travel and Lodging: $68K · Consulting Fee: $37K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $327,175.00 |
| Travel and Lodging | $67,627.20 |
| Consulting Fee | $37,009.25 |
| Food and Beverage | $11,753.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $546,236.86 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Genzyme Corporation | $125,665.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $96,223.66 | 2019-2024 | Dupixent |
| Amgen INC. | $29,833.54 | 2021-2025 | Tezspire |
| Regeneron Pharmaceuticals, INC. | $10,091.92 | 2019-2022 | |
| Glaxosmithkline, LLC. | $9,403.50 | 2019-2024 | Nucala, Trelegy Ellipta |
| Teva Pharmaceuticals USA, INC. | $6,788.72 | 2019-2021 | |
| Abbvie INC. | $4,919.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $2,953.59 | 2024-2025 | |
| Genentech USA, INC. | $432.12 | 2019-2025 | Xolair |
| Csl Behring | $160.65 | 2024 | |
| United Therapeutics Corporation | $157.93 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $130.24 | 2019-2021 | |
| Ars Pharmaceuticals Operations, INC. | $123.65 | 2025 | Neffy |
| Alk-Abello, INC | $86.03 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $79.21 | 2019-2021 | |
| Optinose US, INC. | $41.61 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.